NCM Boston | Oxford Nanopore Technologies
NCM Boston
A
)
Andreas CzechBioNTech, Germany
)
Alex KneubehlBaylor College of Medicine, USA
)
Anne-Sophie LebreCHU Reims, France
)
Ailsa MacCalmanUniversity of Exeter, UK
)
Anastasia McKinlayIndiana University & HHMI, USA
)
Amit MathurSanofi, USA
)
Ana PeresThe University of North Carolina at Chapel Hill, USA
)
Aaron VinyColumbia University Irving Medical Center, USA
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
B
Bronya BoydonMachine Learning Bioinformatician, Oxford Nanopore Technologies
)
Bradley HallAsuragen, USA
Bryan LelandBioinformatics Manager, Commercial Applications, Oxford Nanopore Technologies
)
Benjamin C. ReinerUniversity of Pennsylvania, USA
C
)
Cory BernhardsDEVCOM Chemical Biological Center, USA
)
Chris BrownVP Strategic Programmes, Oxford Nanopore Technologies
)
Colette CôtéPathoQuest, USA
)
Christian GallardoSeattle Children's Research Institute, USA
)
Chun-Chieh LinDartmouth Health, USA
)
Chad PollardWasatch BioLabs, USA
)
Charles A. SwoffordMIT Center for Biomedical Innovation, USA
Carika WeldonCariGenetics, Bermuda
D
)
Daniel K. FabianLonza, UK
Dan FordhamDirector, Strategic Product Management EMEA, Oxford Nanopore Technologies
)
Dmitrijs RotsErasmus MC, Netherlands
)
David VanHouteRegeneron Pharmaceuticals, USA
)
David YarmoshATCC, USA
)
)
G
)
Gabriela PozoUniversity of San Francisco de Quito, Ecuador
)
Gordon SangheraCEO, Oxford Nanopore Technologies
)
Gaston VondenhoffLonza, The Netherlands
H
Heather CarletonCenters for Disease Control & Prevention, USA
)
Helen GunterThe BASE Facility, The University of Queensland, Australia
J
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
)
Justin BeckerDana-Farber Cancer Institute & Massachusetts General Hospital, USA
Jade BartoloAssociate Director, Automation, Oxford Nanopore Technologies
)
Jack ColicchioSound Agriculture, USA
Julie CollensVP, Commercial Operations AMR, Oxford Nanopore Technologies
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
)
J. (Gus) GustafsonUniversity of Washington, USA
K
)
Karine ChoquetUniversity of Sherbrooke, Canada
)
Keith ConnollyModalis Therapeutics, USA
)
Kamil KhanipovThe University of Texas Medical Branch, USA
)
Katherine LawrenceMachine Learning and Bioinformatics Manager, Oxford Nanopore Technologies
L
)
Lucia DaxingerLeiden University Medical Center, Netherlands
)
Lantana GrubVanderbilt University, USA
)
Lakmal JayasingheSenior VP, R&D Biologics, Oxford Nanopore Technologies
)
Laura KamenetzkyCONICET, Argentina
)
Logan MulroneyEMBL-EBI, UK & IIT, Italy
M
)
Matthew BainbridgeRady Children's Institute for Genomic Medicine, USA
)
Michael DeanNational Cancer Institute, USA
)
Mathilde FilserCurie Institute, France
)
Megan L. NoonanWashington University School of Medicine in St. Louis, USA
)
Matt ParkerDirector, Clinical Bioinformatics Software, Oxford Nanopore Technologies
Mile SikicGenome Institute of Singapore, A*STAR, Singapore
)
Mike VellaSenior Director, Machine Learning, Oxford Nanopore Technologies
)
)
P
)
Philipp ReschenederSenior Director, Applications Bioinformatics, Oxford Nanopore Technologies
)
Paula SaffieClinica Santa María, Chile
)
R
)
Ranjith AnandeGenesis, USA
)
Rachel RubinsteinTechnical Product Manager, Software, Oxford Nanopore Technologies
)
Rosemary Sinclair DokosSVP, Product and Programme Management, Oxford Nanopore Technologies
Radhakrishna TirumalaiMerck & Co., USA
)
Rhydian WindsorResearch Scientist, Machine Learning, Oxford Nanopore Technologies
S
)
Stacy L. SpringsMIT Center for Biomedical Innovation, USA
)
Stephanie AbernathyVice President, Sales, Americas, Oxford Nanopore Technologies
)
Stephanie ChrysanthouMemorial Sloan Kettering Cancer Center, USA
Scott HickeyTBC
)
Shilpa KobrenHarvard Medical School, USA
)
Serge MonpoehoRegeneron Pharmaceuticals, USA
Svetlana MadjunkovaCReATe Fertility Centre, Canada
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
)
Samuel ShelburneThe University of Texas MD Anderson Cancer Center, USA
)
Sebastian B. TeitzveryTeitz Consulting, Germany
Speaker TBCNovo Nordisk, Denmark
T
)
Thomas GarciaBaylor College of Medicine, USA
Tasos GogakosArena BioWorks & Massachusetts General Hospital, USA
Tim WalkerApplied Industrial Support Specialist, Oxford Nanopore Technologies
)
)
)
Oxford Nanopore Technologies
Julie Collens
- Job title
- Institution
- VP, Commercial Operations AMR, Oxford Nanopore Technologies
- Biography
Julie Collens is VP, Commercial Operations AMR with Oxford Nanopore Technologies, with responsibility for Sales and Technical Services in the Americas region. She has more than 20 years’ experience in the genomics industry, is a TedX speaker and Board Member of the Alzheimer’s Association in San Diego. She is motivated by the real-world application of genomics to solve large problems in healthcare. Julie spent time on Wall Street as a sell-side equity analyst covering life science tools and molecular diagnostics companies at Robert W. Baird, and in senior marketing strategy roles at Illumina, accelerating the clinical application of genomics in complex diseases. Prior to joining Oxford Nanopore Technologies, she was founder and CEO of Vivid Genomics, a company focused on the implementation of precision medicine to accelerate and improve dementia drug development. Julie completed her BSc at the University of Calgary in Canada and holds a PhD in evolutionary population genetics from The University of Chicago.